CELZ Q3 Loss Widens to $5.58M as Cash Slips to $6.85M; 8.48M Warrants Overhang 7.60M Shares
CELZ is trading near its 52-week low of $0.59 (5.4% above the low) on light trading volume (0.1× avg).
Summary
CELZ posted a $5.58M nine-month net loss and ended September with $6.85M in cash, down from $7.21M at year-end, with warrant exercises supplying the only meaningful inflow. Warrants for 8.48M shares remain outstanding against 7.60M shares.
Key Events · Earnings and Guidance · CELZ
-
Nine-Month Loss Reaches $5.58M
Net loss attributable to CMTH was $5,587,129 for the nine months ended September 30, 2026, versus $4,107,334 a year earlier. The third quarter alone lost $2,670,076.
-
Cash Down to $6.85M
Cash fell to $6,845,741 from $7,208,126 at December 31, 2025. Operating activities used $4,459,905 over the nine months, offset by $4,057,380 of stock and warrant proceeds.
-
Warrant Overhang Exceeds Share Count
Warrants for 8,477,684 shares were outstanding at September 30, 2026 at a $2.65 weighted-average exercise price, against 7,597,557 shares outstanding. The June 2026 inducement added 5,580,680 warrants at $1.60.
-
R&D Inflated by Non-Cash Stock Expense
Research and development rose 52% to $2,602,546 for the nine months, including $1,166,515 of stock-based expense tied to the BioDefense investment — an accounting charge, not cash spent.
Analysis · CELZ · Life Sciences
The balance sheet, not the loss, is the story here. Cash fell to $6,845,741 from $7,208,126 at year-end, and the nine-month operating burn of $4,459,905 was covered only by $4,057,380 of warrant-exercise proceeds. Strip out that financing and the company is consuming roughly $0.5M a month. Against 7,597,557 shares outstanding sit warrants for 8,477,684 shares at a $2.65 weighted-average strike — more potential shares than exist today, though at a strike far above the current price. The quarter also carried $1,166,515 of non-cash stock expense tied to the BioDefense stake, which inflates the R&D line without touching cash. Separately, the CEO bought the company's 80% Bionance interest for $44,000 on October 23, 2026, unwinding a related-party investment at a fraction of the $125,000 originally contributed.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELZ was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.59 to $4.72. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.